Live feed21:58:00·748dPRReleasevia QuantisnowGeron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaByQuantisnow·Wall Street's wire, on your screen.GERN· Geron CorporationHealth Care
